Cardiovascular diseases (CVD) remain a major health issue and a grave socio-economic burden, being the No. 1 killer in major industrial countries and the main reason for frequent rehospitalization [1] . In recent years, unmet needs for a distinct cardiovascular risk assessment allowing for standardized guidelines on personalized therapy have led to an intensive research on biomarkers. Even in this post-cTn (cardiac troponin) and post-BNP (B-type natriuretic peptide) era, there and innovative methods and tools for diagnosis and evidenceguided management of CVD. Under this context, the basic research and clinical use of biomarkers have gained a tremendous momentum in the past decade. The use of single or multiple biomarkers as reliable and reproducible indicatives of the risk, severity, and progression stage of CVD greatly enhances the diagnostic decision and prognostic ability of emergency department physicians, cardiologists, and cardiovascular surgeons in their routine patient care duties. The prudential utilization of valid biomarkers in clinical practice can reduce time and costs for an accurate diagnosis and proper personalized therapy of CVD patients. As suggested in Figure 1 , biomarker testing may play a central role in the evidence-based Cardiovascular Medicine and it can in turn promote the improved clinical outcome, better quality of life, and alleviated socioeconomic burden of CVD.
Accordingly, this Special Issue of Acta Pharmacologica Sinica was planned to provide a forum for high quality original research and review articles to showcase the most recent advances in translational research and clinical practices on a wide-spectrum array of conventional as well as novel cardiovascular biomarkers. Coverage of this Special Issue encompasses various forms of large or small molecules, such as proteins, peptides, cytokines, microRNAs, and metabolic by- This Special Issue covers a variety of pathological types of CVD, including acute myocardial infarction (AMI) [2] [3] [4] [5] , heart failure [6] , aortic aneurysms [7, 8] , carotid restenosis [9] , pulmonary arterial hypertension (PAH) [10] , and cardiac amyloidosis [11] . Several review articles provided in-depth analyses on the important diagnostic and prognostic roles of zinc [12] , oxylipins [13] , and leptin [14] in the fundamental cellular signaling and pathogenic processes in CVD and diabetes. Notably, all the 7 original research articles are clinical research on Asian patients with AMI [5] or PAH [10] as well as European patients with AMI [2] , chronic heart failure [6] , vascular aneurysm [7] or restenosis [9] , and stroke [15] . It is noteworthy that 4 review articles [4, [16] [17] [18] and 2 original research papers [2, 10] in this Special Issue are focusing on a cutting-edged topic concerning the potential roles of circulating noncoding RNAs (ncRNAs), which include microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs), in serving as a new generation of biomarkers for CVD. Among these elegant works, Bayoumi et al. reviewed the circular noncoding RNAs as potential therapies and circulating biomarkers for CVD [18] . The similar topic was also thoroughly analyzed by Zhou et al [17] and Stepien et al [16] , who provided their own perspectives. Two other papers by Wang et al [4] and Song et al [10] provided more focused discussions respectively on the use of microRNAs for early detection of CVD such as AMI [4] and pulmonary hypertension [10] . We wish this panel of 6 articles may help the readers to gain a comprehensive grasp on the upcoming trend of using miRNAs, lncRNAs, and circRNAs as the newest class of CVD biomarkers that will be eventually utilized in the clinical settings considering the above-discussed keen interests and intensive investigations in this research area.
Another highlighted area of discussion in this Special Issue is on the technological and methodological innovations for the CVD biomarker detection. Our invited experts have communicated their original research results using various technologies from advanced chip-based digital PCR [2] to 2D-gel analysis [5] . They also thoroughly reasoned the needs for multiplex approach to enhance diagnostic accuracy superior to the single biomarker detection [19] . In brief, we believe that these collective efforts will be instrumental for future research and technological development of new CVD biomarkers that can be used for saving lives and improving clinical outcomes in tens of millions CVD patients worldwide. For these meaningful endeavor and noble cause,
